Onco Actu du 16 mai 2018

	1. Biologie
As D.I.Y. Gene Editing Gains Popularity, ‘Someone Is Going to Get Hurt’ [NY Times] After a virus was created from mail-order DNA, scientists are sounding the alarm about the genetic tinkering carried out in garages and living rooms.
	3.1.1 Prévention - Tabac - e-cigs
Florida man dies in e-cigarette explosion, police say [CNN] The cause of death is identified as a projectile wound to the head, Bill Pellan, director of investigations at the Pinellas County Medical Examiner's Office, said Tuesday. The projectile was from a section of an e-cigarette.
	4.3 Dép., diag. & prono. - Industriels
Illumina Acquires Edico Genome to Accelerate Genomic Data Analysis [Illumina] Edico’s DRAGEN® Bio-IT Platform Delivers Faster, Streamlined Output for Next-Generation Sequencing.
BioAffinity Seeking $5M for Cancer Diagnostic, Adds Board Member [Xconomy] The San Antonio-based company plans to use the new financing to commercialize its diagnostic, CyPath, for lung cancer in the U.S. and the European Union. CyPath is a noninvasive test that analyzes sputum—mucus from deep in the lung—for cancer cells.
A Need for Speed: Illumina Acquires San Diego’s Edico Genome [Xconomy] Edico developed technology that combines a specialized processor and chipset with proprietary software to address a bottleneck in the process of reading the short DNA segments produced in genome sequencing, and aligning them with a reference genome.
	4.9 Dép., diag. & prono. - Sein
Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients [Agendia] The successful tender includes both Agendia’s centralized laboratory service which enables physicians to send their patient’s tumor specimen for analysis using the MammaPrint and BluePrint tests at the Company’s CLIA-certified and CAP-accredited laboratories in Amsterdam, the Netherlands, and the next-generation sequencing-based MammaPrint BluePrint Kit.
Agendia Breast Cancer Tests Adopted by French Hospital Group [Genome Web] Agendia said today that French hospital group Unicancer has selected its MammaPrint and BluePrint tests for use in a group of 18 comprehensive cancer centers.
	5.10 Traitements - Essais
New cancer clinical trial model promises to cut costs and development time [Pharmafile] Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the better design and operation of clinical trials into the treatment of cancerous tumours.
	5.12.2 Immunothérapies - CAR-T
Gilead fortifies its pioneering cell therapy status, expanding into three new facilities and teaming with NCI [EndPoints] In the Netherlands, Gilead has leased a 117,000 square-foot manufacturing site in Hoofddorp, allowing the company to make and deliver cell therapies to people living with cancer in Europe.
	5.12.4 Immunothérapies - Essais
Patient Registries to Bolster Cell- and Gene-Therapy Clinical Trial Data [The Scientist] As the first personalized cell and gene therapies are approved from small clinical trials, researchers propose the creation of publicly accessible databases to pull together real-world results.
	5.2 Pharma
Seattle’s Nohla closes $45M to bring novel stem cell treatment for leukemia to late-stage trials [EndPoints] The startup is tackling a novel stem cell treatment for leukemia that uses cells from donated umbilical cord blood. It could be more effective than traditional bone marrow transplants.
	5.2.1 Pharma - Partenariats
Roche pens death notice for NewLink IDO/TDO cancer collab [FierceBiotech] This comes after a torrid few months for IDO research.
	5.2.3 Pharma - économie
Novartis CEO Vas Narasimhan faces a heap of burning questions — but so far offers no public answers [EndPoints] Novartis recognizes it faces a crisis. But for now, there’s no clear plan to deal with it in any kind of public way.
	5.4 Traitements - Economie
After outcry, drugmakers decide not to triple the price of a cancer pill [Washington Post] Physicians, who say they frequently adjust the dose of Imbruvica to avoid interactions with other drugs or side effects, had been concerned the dosing change could delay their ability to rapidly change patients' dosages as needed.
	5.5.1.1 ASCO (général) - Industriels
Myriad Genetics to Present Eight Studies at the 2018 American Society of Clinical Oncology Annual Meeting [Myriad] "Importantly, our presentations will focus on new advances in predicting breast cancer recurrence and the need for chemotherapy, the role of hereditary cancer testing in preventing cancer or optimizing treatment plans, and novel companion diagnostics for helping guide medication selection for patients with breast or ovarian cancers."
	6.1 Observation
More men with low-risk prostate cancer are forgoing aggressive treatment [Washington Post] “I think it's hugely important,” said Otis Brawley, chief medical officer of the American Cancer Society, who was not involved in the study. “Remember that until 2010, a man diagnosed with prostate cancer was told to get your prostate out, next week at the latest.”
	6.10.1 Politiques (USA)
Azar threatens drugmakers with Trump's temper if they hike prices for no reason [FiercePharma] Azar indirectly singled out Celgene's Revlimid as an example of how the flawed U.S. pricing system allows pharma companies to "run up huge profits" while patients struggle to afford their meds.
As Trump railed against the ‘drug lobby,’ lawmakers funded by pharma watched from Rose Garden [STAT] Many of the lawmakers who were present are in fact at the center of the pharmaceutical industry’s efforts to lobby Congress.
	6.6 Publications
Why Was Springer Nature’s IPO Withdrawn? [The Scholarly Kitchen] Perhaps the future is, and indeed much of the value will be, not about publishing as we have known it but about research workflow services. Through its new Dimensions product, for example, Digital Science is positioning itself to transform the nature of content distribution and access, one of several major areas where it is fostering entirely new businesses.